Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Rubella and Congenital Rubella Syndrome

Generalities
Agent Rubella virus, genus Rubullovirus, family Togaviridae
Incubation period 14-17 days (range 14-21 days)
Period of transmissibility - 7 days before rash and 4 days after rash onset
- From congenital rubella: infants shed the virus for several months after birth
Reservoir Humans
Modes of transmission - Person-to-person: direct contact with droplets
- Infants with Congenital Rubella Syndrome shed large quantities of virus in their pharyngeal secretions and urine.
- Materno-foetal transmission: 90% of infants born to women infected with rubella during the 1st trimester. The risk of transmission is 10-20% by the 16th week, and rare after the 20th week.
Clinical presentation - Febril maculo-papular rash
- Complications: thrombocytopenia (1/3000), post-infectious encephalitis (1/6000), rarely chronic arthritis
- Congenital Rubella Syndrome: Congenital malformation as deafness, cataracts, microphtalmia, congenital glaucoma, pigmentary retinopathy, nystagmus, microcephaly, meningo-encephalitis, mental retardation, patent ductus arteious, atrial or ventricular septal defects, other congenital heart disease, purpura, hepatosplenomegaly, jaundice, radiolucent bone disease
Resources
Case definitions - MOPH circular no 12 (2013): Acquired Rubella
- MOPH circular no 45 (2007): Congenital Rubella Syndrome
Forms - Rash reporting form
- CRS reporting form
- Rash investigation form
- CRS investigation form
Data - Rubella 2021
- Rubella 2020
- Rubella 2019
- Rubella 2018
- Rubella 2017
- Rubella 2016
- Rubella 2015
 
    ...
    18
ATC Name B/G Ingredients Dosage Form Price
B01AC17 AGGRASTAT B Tirofiban hydrochloride monohydrate - 0.25mg/ml 0.25mg/ml Injectable concentrated solution 18,280,324 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 162mg/0.9ml 162mg/0.9ml Injectable solution 79,959,812 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 200mg/10ml 200mg/10ml Injectable concentrated solution 25,485,937 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 400mg/20ml 400mg/20ml Injectable concentrated solution 47,925,322 L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 80mg/4ml 80mg/4ml Injectable concentrated solution 11,127,864 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 21,176,745 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution + solvent 34,948,930 L.L
D10AD01 A-RET G Tretinoin - 0.05% 0.05% Cream 335,961 L.L
D10AD01 AVOTIN-A G Tretinoin - 0.05% 0.05% Cream 440,780 L.L
D10AD06 AKLIEF B Trifarotene - 50mcg/g 50mcg/g Cream 4,359,425 L.L
C09CA03 ANGINET G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
C09CA03 ARBITEN 160 G Valsartan - 160mg 160mg Tablet 544,256 L.L
C09DX01 ARBITEN AM PLUS G Valsartan - 160mg, Amlodipine - 5mg, Hydrochlorothiazide - 12.5mg Tablet 857,372 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet 544,256 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet 579,196 L.L
C09DX01 ANGIOSAR PLUS G Valsartan - 320mg, Amlodipine - 10mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,689,210 L.L
C09CA03 ANGINET G Valsartan - 80mg 80mg Tablet, film coated 387,027 L.L
C09CA03 ARBITEN 80 G Valsartan - 80mg 80mg Tablet 387,027 L.L
R03AL03 ANORO ELLIPTA B Vilanterol - 25mcg, Umeclidinium bromide - 62.5mcg Inhalation powder 5,181,575 L.L
A11CC05 ALTO D 10.000 G Vitamin D3 - 10,000IU 10,000IU Capsule 895,895 L.L
A11CC05 ALTUM-D3 G Vitamin D3 - 10,000IU 10,000IU Capsule 561,342 L.L
A11CC05 ALTUM G Vitamin D3 - 50,000IU 50,000IU Capsule, hard 712,620 L.L
V07AB01 ARWAN WFI G Water for injection - Water for injection, irrigation 399,915 L.L
M05BA08 ACLASTA B Zoledronic acid (monohydrate) - 5mg/100ml 5mg/100ml Injectable solution 21,075,062 L.L
    ...
    18
Sitemap
© Copyrights reserved to Ministry of Public Health 2025